<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712957</url>
  </required_header>
  <id_info>
    <org_study_id>NEO6860-OA-01</org_study_id>
    <nct_id>NCT02712957</nct_id>
  </id_info>
  <brief_title>A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain</brief_title>
  <official_title>A Proof-of-Concept, Randomized, Double Blind, Placebo and Active Control, 3-Period, Crossover Design Study Assessing NEO6860 in Patients With Pain Associated With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neomed Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neomed Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess NEO6860, a modality selective TRPV1 antagonist, in
      patients with pain associated with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be randomized, double blind, placebo and active control, a 3-way, 3-period
      crossover design, where each of the estimated 50 enrolled patients will receive alternately
      (i) NEO6860 (500 mg bid), (ii) placebo and (iii) Naproxen (500 mg bid). To ensure blinding,
      double dummy techniques will be used, so that at each period, patient will receive an oral
      liquid suspension (NEO6860 or its placebo) and one capsule (naproxen or its placebo).

      Following a screening period, a maximum of 28 days before dosing, subjects will be randomized
      to one of the scheduled sequences. At each dosing period, subjects will be requested to
      participate in 2 clinic visits:

        -  One residential visit, the morning of investigational product dosing. Subjects will stay
           in the Clinical Research Unit approximately 13 hours

        -  One end of period visit, 24 h after first dosing A total of 2 washout periods of 1 to 3
           weeks will separate the dosing periods. Once the 3 dosing periods will be completed, the
           subjects will come back to the clinic for a follow up visit (7 to 10 days post last
           dose).

      Note: for a subpopulation, at one site, an assessment of heat pain threshold and tolerance
      will be conducted requiring a residential period of approximately 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 24, 2016</completion_date>
  <primary_completion_date type="Actual">November 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Numerical Rating Scale (NRS, 0-10) from baseline after the staircase test to 8 hours post first dose after the staircase test on the index knee.</measure>
    <time_frame>8 hours post dosing. This endpoint will be collected 3 times, 8 hours post dosing for each period: NEO6860, naproxen and placebo.</time_frame>
    <description>Patients are asked to step fully up onto a 8-inch (20 cm) high platform with both feet and back down a total of 24 times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC 3.1 Index Likert pain subscale</measure>
    <time_frame>from baseline (screening) to 24 hour recall post 1 day treatment at each of the 3 periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC)</measure>
    <time_frame>24 hour post 1 day treatment at each of the 3 periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Pain</condition>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>NEO6860</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEO6860</intervention_name>
    <description>TRPV1 antagonist</description>
    <arm_group_label>NEO6860</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEO6860 placebo</intervention_name>
    <description>Inactive substance</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>NSAID</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen placebo</intervention_name>
    <description>inactive substance</description>
    <arm_group_label>NEO6860</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 18.0 and 35.0 kg/m2 inclusive;

          -  Patients diagnosed with osteoarthritis of the knee, according to American College of
             Rheumatology (ACR) guidelines, by meeting at least 3 of the following: age &gt; 50,
             morning stiffness &lt; 30 minutes, crepitus on active motion, bone tenderness, bone
             enlargement, no palpable warmth of synovium;

          -  Grade I, II or III using Kellgren-Lawrence classification on an X-Ray of the knee

          -  WOMAC pain subscale â‰¥ 8

          -  R square of the Focused Analgesia Selection Task (FAST) outcome value greater than
             0.70

        Exclusion Criteria:

          -  Patients with, or with a history of, any clinically significant disorders (including
             fibromyalgia and other painful disorders) which may interfere with the primary
             objectives of the study

          -  Patients treated in the previous 3 months with topical capsaicin or intra-articular
             corticosteroids;

          -  Patients with a contra-indication for the use of Naproxen or acetaminophen;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan A Chiche, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neomed Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diex Recherche Montreal Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2Y 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Sherbrooke Inc</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

